

Arsenic trioxide

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL concentrate for solution for infusion; 2 mg per mL concentrate for solution for infusion	Acute myeloid leukaemia with recurrent genetic abnormalities

Asparaginase

Section	Indications
Cytotoxic medicines Powder for injection: 10 000 IU in vial. Parenteral > General injections > unspecified: 10000 IU in vial powder for injection	Unspecified malignant neoplasms of ill-defined or unspecified sites Lymphoid leukaemia, not elsewhere classified

Azacitidine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 100 mg in vial powder for injection	Myeloid leukaemia

Bendamustine

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 45 mg per 0.5 mL; 180 mg per 2 mL	Chronic lymphocytic leukaemia or small lymphocytic lymphoma Follicular lymphoma

Bleomycin

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 15000 IU in vial (as sulfate)	Germ cell tumour of testis Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary Unspecified malignant neoplasms of ill-defined or unspecified sites

Calcium folinate (leucovorin calcium)

Section	Indications
<p>Cytotoxic medicines</p> <p>Oral > Solid: 15 mg tablet</p> <p>Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule</p> <p>Parenteral > General injections > unspecified: 3 mg per mL in 10 mL ampoule; 7.5 mg per mL in 2 mL ampoule; 10 mg per mL in 5 mL ampoule</p> <p>Oral > Solid > tablet: 15 mg; 5 mg; 25 mg</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasm metastasis in large intestine</p> <p>Malignant trophoblastic neoplasms of placenta</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Malignant neoplasms of rectum</p> <p>Malignant neoplasms of colon</p>

Capecitabine

Section	Indications
<p>Cytotoxic medicines</p> <p>Oral > Solid > tablet: 150 mg; 500 mg</p>	<p>Other specified malignant neoplasms of breast</p> <p>Malignant neoplasm metastasis in large intestine</p> <p>Malignant neoplasms of rectum</p> <p>Malignant neoplasms of colon</p>

Carboplatin

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 50 mg per 5 mL; 150 mg per 15 mL; 450 mg per 45 mL; 600 mg per 60 mL</p>	<p>Other specified gliomas of brain</p> <p>Other specified carcinomas of ovary</p> <p>Retinoblastoma</p> <p>Other specified malignant neoplasms of bronchus or lung</p> <p>Malignant neoplasms of nasopharynx</p> <p>Malignant neoplasms of kidney, except renal pelvis</p> <p>Malignant neoplasms of breast</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Malignant neoplasms of lip, oral cavity or pharynx</p> <p>Malignant neoplasms of cervix uteri</p> <p>Other specified malignant neoplasms of the ovary</p> <p>Germ cell tumour of testis</p>

Chlorambucil

Section	Indications
Cytotoxic medicines Oral > Solid: 2 mg tablet	Unspecified malignant neoplasms of ill-defined or unspecified sites
	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Cisplatin

Section	Indications
Cytotoxic medicines Parenteral > General injections > unspecified: 10 mg in vial powder for injection; 50 mg in vial powder for injection Parenteral > General injections > IV: 50 mg per 50 mL; 100 mg per 100 mL; 10 mg per 10 mL; 20 mg per 20 mL	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Other specified malignant neoplasms of the ovary Other specified malignant neoplasms of bronchus or lung Malignant neoplasms of nasopharynx Germ cell tumour of testis Osteosarcoma of bone and articular cartilage of unspecified sites Malignant neoplasms of lip, oral cavity or pharynx Malignant neoplasms of cervix uteri

Cladribine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 1 mg per mL in 10 mL vial; 2 mg per mL in 5 mL vial	Langerhans cell histiocytosis

Cyclophosphamide

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Oral > Solid: 25 mg tablet	Other specified malignant neoplasms of breast
Parenteral > General injections > unspecified: 500 mg in vial powder for injection	Malignant trophoblastic neoplasms of placenta
Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection	Follicular lymphoma
Oral > Solid > dosage form: 25 mg; 50 mg	Malignant neoplasms of breast
	Chronic lymphocytic leukaemia or small lymphocytic lymphoma
	Rhabdomyosarcoma primary site
	Hodgkin lymphoma
	Diffuse large B-cell lymphomas
	Plasma cell myeloma
	Other specified gliomas of brain
	Burkitt lymphoma including Burkitt leukaemia
	Malignant neoplasms of kidney, except renal pelvis
	Ewing sarcoma of bone and articular cartilage of unspecified sites
	Lymphoid leukaemia, not elsewhere classified
	Anaplastic large cell lymphoma, ALK-negative
	Anaplastic large cell lymphoma, ALK-positive

Cytarabine

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Parenteral > General injections > unspecified: 100 mg in vial powder for injection	Lymphoid leukaemia, not elsewhere classified
Parenteral > General injections > unspecified: 100 mg in vial powder for injection; 100 mg per mL in vial	Myeloid leukaemia
	Acute myeloid leukaemia with recurrent genetic abnormalities
	Burkitt lymphoma including Burkitt leukaemia
	Anaplastic large cell lymphoma, ALK-negative
	Anaplastic large cell lymphoma, ALK-positive
	Langerhans cell histiocytosis

Dacarbazine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 100 mg in vial powder for injection; 200 mg in vial powder for injection	Hodgkin lymphoma

Dactinomycin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 500 µg in vial powder for injection	Malignant trophoblastic neoplasms of placenta Unspecified malignant neoplasms of ill-defined or unspecified sites Malignant neoplasms of kidney, except renal pelvis Rhabdomyosarcoma primary site Ewing sarcoma of bone and articular cartilage of unspecified sites

Daunorubicin

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 50 mg in vial (as hydrochloride) powder for injection; 20 mg in vial (as hydrochloride) powder for injection; 2 mg per mL in vial (as hydrochloride); 5 mg per mL in vial (as hydrochloride)	Acute myeloid leukaemia with recurrent genetic abnormalities Lymphoid leukaemia, not elsewhere classified Myeloid leukaemia

Docetaxel

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 20 mg per mL; 40 mg per mL	Other specified malignant neoplasms of breast Malignant neoplasms of breast Malignant neoplasms of prostate Unspecified malignant neoplasms of ill-defined or unspecified sites

Doxorubicin

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 10 mg in vial (hydrochloride); 50 mg in vial (hydrochloride)</p> <p>Parenteral > General injections > IV: 10 mg in vial (hydrochloride) powder for injection; 50 mg in vial (hydrochloride) powder for injection; 2 mg per mL in 5 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Rhabdomyosarcoma primary site</p> <p>Malignant neoplasms of breast</p> <p>Hodgkin lymphoma</p> <p>Diffuse large B-cell lymphomas</p> <p>Plasma cell myeloma</p> <p>Follicular lymphoma</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasms of kidney, except renal pelvis</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Anaplastic large cell lymphoma, ALK-negative</p> <p>Other specified malignant neoplasms of breast</p> <p>Anaplastic large cell lymphoma, ALK-positive</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Kaposi sarcoma of unspecified primary site</p>

Doxorubicin (as pegylated liposomal)

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 2 mg per mL in 10 mL vial (hydrochloride); 2 mg per mL in 25 mL vial (hydrochloride)</p>	<p>Kaposi sarcoma of unspecified primary site</p>

Etoposide

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule</p> <p>Oral > Solid: 100 mg capsule</p> <p>Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule; 100 mg in vial powder for injection (as phosphate)</p> <p>Oral > Solid: 100 mg capsule; 50 mg capsule</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Myeloid leukaemia</p> <p>Other specified malignant neoplasms of the ovary</p> <p>Other specified malignant neoplasms of bronchus or lung</p> <p>Germ cell tumour of testis</p> <p>Malignant trophoblastic neoplasms of placenta</p> <p>Malignant neoplasms of kidney, except renal pelvis</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Hodgkin lymphoma</p> <p>Retinoblastoma</p> <p>Anaplastic large cell lymphoma, ALK-positive</p> <p>Anaplastic large cell lymphoma, ALK-negative</p>

Fludarabine

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 50 mg in vial (fludarabine phosphate) powder for injection</p> <p>Oral > Solid: 10 mg tablet (fludarabine phosphate)</p>	Chronic lymphocytic leukaemia or small lymphocytic lymphoma

Fluorouracil

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Parenteral > General injections > IV: 50 mg per mL in 5 mL ampoule	Malignant neoplasms of nasopharynx
Parenteral > General injections > IV: 50 mg per mL in vial	Malignant neoplasm metastasis in large intestine
	Malignant neoplasms of breast
	Malignant neoplasms of rectum
	Malignant neoplasms of colon

Gemcitabine

Section	Indications
Cytotoxic medicines	Other specified carcinomas of ovary
Parenteral > General injections > IV: 200 mg in vial powder for injection; 1 g in vial powder for injection	Other specified malignant neoplasms of bronchus or lung

Hydroxycarbamide (hydroxyurea)

Section	Indications
Cytotoxic medicines	Squamous cell carcinoma of oropharynx
Oral > Solid: 200 mg; 250 mg; 300 mg; 400 mg; 500 mg; 1 g	Chronic myeloid leukaemia, not elsewhere classified
Oral > Solid > dosage form: 200 mg; 300 mg; 400 mg; 500 mg; 1 g; 100 mg	

Ifosfamide

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 500 mg in vial powder for injection; 1 g in vial powder for injection; 2 g in vial powder for injection</p> <p>Parenteral > General injections > IV: 1 g in vial powder for injection; 2 g in vial powder for injection</p>	<p>Other specified malignant neoplasms of the ovary</p> <p>Germ cell tumour of testis</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Rhabdomyosarcoma primary site</p> <p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasms of kidney, except renal pelvis</p> <p>Anaplastic large cell lymphoma, ALK-negative</p> <p>Anaplastic large cell lymphoma, ALK-positive</p>

Irinotecan

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 40 mg per 2 mL in 2 mL vial; 100 mg per 5 mL in 5 mL vial; 500 mg per 25 mL in 25 mL vial</p>	<p>Malignant neoplasm metastasis in large intestine</p> <p>Malignant neoplasms of kidney, except renal pelvis</p> <p>Rhabdomyosarcoma primary site</p>

Melphalan

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 50 mg in vial powder for injection</p> <p>Oral > Solid: 2 mg</p>	<p>Plasma cell myeloma</p>

Mercaptopurine

Section	Indications
<p>Cytotoxic medicines</p> <p>Oral > Solid: 50 mg tablet</p> <p>Oral > Liquid: 20 mg per mL</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Acute myeloid leukaemia with recurrent genetic abnormalities</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Langerhans cell histiocytosis</p>

Methotrexate

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 50 mg in vial (as sodium salt)</p> <p>Oral > Solid: 2.5 mg (as sodium salt)</p> <p>Parenteral > General injections > IV: 50 mg in vial (as sodium salt); 50 mg per 2 mL; 1000 mg per 10 mL concentrated injection</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Acute myeloid leukaemia with recurrent genetic abnormalities</p> <p>Malignant trophoblastic neoplasms of placenta</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasms of breast</p> <p>Osteosarcoma of bone and articular cartilage of unspecified sites</p> <p>Anaplastic large cell lymphoma, ALK-negative</p> <p>Anaplastic large cell lymphoma, ALK-positive</p> <p>Langerhans cell histiocytosis</p>

Oxaliplatin

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 50 mg in vial powder for injection; 100 mg in vial powder for injection; 50 mg per 10 mL in 10 mL vial; 100 mg per 20 mL in 20 mL vial; 200 mg per 40 mL in 40 mL vial</p>	<p>Malignant neoplasm metastasis in large intestine</p> <p>Malignant neoplasms of colon</p>

Paclitaxel

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 6 mg per mL</p>	<p>Other specified malignant neoplasms of the ovary</p> <p>Other specified malignant neoplasms of bronchus or lung</p> <p>Malignant neoplasms of nasopharynx</p> <p>Kaposi sarcoma of unspecified primary site</p> <p>Other specified malignant neoplasms of breast</p> <p>Other specified carcinomas of ovary</p> <p>Malignant neoplasms of breast</p> <p>Malignant neoplasms of cervix uteri</p>

Pegaspargase

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 3750 units per 5 mL in vial; 3750 units in vial powder for injection	Lymphoid leukaemia, not elsewhere classified

Procarbazine

Section	Indications
Cytotoxic medicines	Unspecified malignant neoplasms of ill-defined or unspecified sites
Oral > Solid: 50 mg (as hydrochloride)	Hodgkin lymphoma

Realgar-indigo naturalis formulation

Section	Indications
Cytotoxic medicines Oral > Solid: 270 mg (containing tetra-arsenic tetra-sulfide 30 mg)	Acute myeloid leukaemia with recurrent genetic abnormalities

Tioguanine

Section	Indications
Cytotoxic medicines Oral > Solid: 40 mg	Lymphoid leukaemia, not elsewhere classified

Vinblastine

Section	Indications
Cytotoxic medicines Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate) Parenteral > General injections > IV: 10 mg in vial (vinblastine sulfate); 10 mg per 10 mL in vial (vinblastine sulfate)	Unspecified malignant neoplasms of ill-defined or unspecified sites Other specified gliomas of brain Kaposi sarcoma of unspecified primary site Hodgkin lymphoma Other specified malignant neoplasms of the ovary Germ cell tumour of testis Anaplastic large cell lymphoma, ALK-positive Anaplastic large cell lymphoma, ALK-negative Langerhans cell histiocytosis

Vincristine

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate)</p> <p>Parenteral > General injections > IV: 1 mg in vial (vincristine sulfate); 5 mg in vial (vincristine sulfate); 1 mg per mL in vial (vincristine sulfate); 2 mg per 2 mL in vial (vincristine sulfate)</p>	<p>Unspecified malignant neoplasms of ill-defined or unspecified sites</p> <p>Other specified gliomas of brain</p> <p>Malignant trophoblastic neoplasms of placenta</p> <p>Follicular lymphoma</p> <p>Kaposi sarcoma of unspecified primary site</p> <p>Rhabdomyosarcoma primary site</p> <p>Hodgkin lymphoma</p> <p>Diffuse large B-cell lymphomas</p> <p>Retinoblastoma</p> <p>Burkitt lymphoma including Burkitt leukaemia</p> <p>Malignant neoplasms of kidney, except renal pelvis</p> <p>Ewing sarcoma of bone and articular cartilage of unspecified sites</p> <p>Lymphoid leukaemia, not elsewhere classified</p> <p>Langerhans cell histiocytosis</p>

Vinorelbine

Section	Indications
<p>Cytotoxic medicines</p> <p>Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial</p> <p>Parenteral > General injections > IV: 10 mg per mL in 1 mL vial; 10 mg per mL in 5 mL vial</p> <p>Oral > Solid > capsule: 20 mg; 30 mg; 80 mg</p>	<p>Other specified malignant neoplasms of bronchus or lung</p> <p>Other specified malignant neoplasms of breast</p> <p>Rhabdomyosarcoma primary site</p>